Navigation Links
Children's Hospital researchers identify molecular 'switch' that could save very young lives
Date:12/4/2007

A team of researchers at Childrens Hospital of Pittsburgh of UPMC have identified a molecular switch that, when blocked, may help reverse necrotizing enterocolitis (NEC), a leading cause of death in premature infants.

Results of the research were presented by principal investigator David J. Hackam, MD, PhD, a pediatric surgeon and scientist at Childrens Hospital, this weekend at the 4th Annual Meeting of the American Society for Cell Biology.

NEC is a severe inflammatory disease of the intestine that occurs in about 5 percent of premature births and can be fatal in as many as half of those cases. In extreme cases, NEC leads to perforation of the intestine, a condition that can be fatal if not treated with emergency surgery. NEC is increasing in frequency due to the increased survival of premature infants, according to Dr. Hackam.

Working in the laboratory with an animal model of NEC, Dr. Hackams team found that when molecular receptor known as Toll-like receptor-4 (TLR4) was blocked, they enabled the repair of damaged intestinal tissue that is the hallmark of NEC.

This Toll-like receptor is a defense mechanism that normally switches on the intestines immune response. But in some premature infants, stresses like oxygen deprivation and toxins caused by underdeveloped lungs stimulate the overproduction of TLR4. Like an unstoppable alarm, this signaling eventually can lead to cell death and prevent enterocytes from migrating to close wounds in the intestine, which can result in intestinal failure, Dr. Hackam said. By interfering with the production of another molecule associated with TLR4 known as focal adhesion kinase (FAK), we were able to silence the TLR4 alarm in intestinal cells.

Blocking the TLR4 signal allowed enterocytes to once again migrate and heal the damaged intestinal tissue. Dr. Hackams team is continuing to research the development of treatment strategies that would block the TLR4 switch by influencing its interaction with FAK. Potentially, these novel treatments could be administered as a component of oral feeds for infants, Dr. Hackam said.


'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Related medicine news :

1. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
2. Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash
3. New research explores newborn in-hospital weight loss
4. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
5. Norwalk virus: Cruise ship illness challenging and costly to hospitals, too
6. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
7. Billy Graham Home After Hospitalization:
8. Alvarado Hospital Files Countersuit Against Blue Shield
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
11. Annual flu shot cuts need for doctors visits, hospitalization among children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... QualDerm Partners , a ... today announced Cumberland Skin Surgery and Dermatology has joined the company ... in both Hermitage and Lebanon, Tennessee, provides comprehensive general dermatology and skin cancer ...
(Date:8/16/2017)... Island, NY (PRWEB) , ... August 16, 2017 , ... ... with IV starts and blood draws. By broadly deploying AccuVein devices, Maury Regional Medical ... takes much of the guesswork out of a needle stick and more importantly, helps ...
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , is honored ... The annual list identifies the nation’s top physicians, in a variety of specialties. This ... the top of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted ...
(Date:8/16/2017)... ... , ... A global leader in the treatment of clubfoot, CURE International ... states—bringing the country one step closer to eliminating clubfoot as a lifelong disability by ... track to enroll 10,000 children in the clubfoot treatment program in this year alone. ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... states: “Drying the endoscope after every reprocessing cycle, both between patient procedures and ... and nosocomial infections. Drying is as important to the prevention of disease transmission ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
(Date:7/28/2017)... 2017 EnvoyHealth, a Diplomat company, has partnered with ... CleverCap LITE, a technology designed to improve patient medication ... health technology solutions and services that help track and ... CleverCap LITE offers medication monitoring and control for ... Records date and time ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: